Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Allergan PLC (NYSE:AGN)

Paying users zone. Data is hidden behind: .

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Balance Sheet: Liabilities and Stockholders’ Equity

Beginner level

The balance sheet provides creditors, investors, and analysts with information on company’s resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company’s assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Allergan PLC, consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Accrued third-party rebates
Litigation-related reserves and legal fees
Accrued payroll and related benefits
Accrued returns and other allowances
Accrued R&D expenditures
Interest payable
Royalties payable
Accrued pharmaceutical fees
Accrued severance, retention and other shutdown costs
Accrued non-provision taxes
Accrued selling and marketing expenditures
Current portion of contingent consideration obligations
Dividends payable
Other accrued expenses
Accrued expenses
Accounts payable
Accounts payable and accrued expenses
Income taxes payable
Current portion of long-term debt and capital leases
Current portion of lease liability, operating
Current liabilities held for sale
Current liabilities
Long-term debt and capital leases, excluding current portion
Lease liability, operating, excluding current portion
Acquisition related contingent consideration liabilities
Long-term pension and post retirement liability
Legacy Allergan deferred executive compensation
Accrued R&D milestone
Long-term contractual obligations
Deferred revenue
Product warranties
Long-term severance and restructuring liabilities
Other long-term liabilities
Other long-term liabilities
Long-term liabilities held for sale
Other taxes payable
Deferred tax liabilities
Long-term liabilities
Total liabilities
Preferred shares, $0.0001 par value per share
Ordinary shares; $0.0001 par value per share
Additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Shareholders’ equity
Noncontrolling interest
Total equity
Total liabilities and equity

Based on: 10-K (filing date: 2020-02-18), 10-K (filing date: 2019-02-15), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Allergan PLC’s current liabilities decreased from 2017 to 2018 but then increased from 2018 to 2019 exceeding 2017 level.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Allergan PLC’s long-term liabilities decreased from 2017 to 2018 and from 2018 to 2019.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Allergan PLC’s total liabilities decreased from 2017 to 2018 and from 2018 to 2019.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity’s stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Allergan PLC’s shareholders’ equity decreased from 2017 to 2018 and from 2018 to 2019.